Respiratory Collaboration and Licensing Agreements Trends Analysis Report 2024 with Upfront, Milestone, and Royalties Data for 415 Deals
September 25, 2024 09:19 ET
|
Research and Markets
Dublin, Sept. 25, 2024 (GLOBE NEWSWIRE) -- The "Respiratory Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
Chronic Refractory Cough Pipeline Landscape Report 2024 Featuring GSK and Trevi Therapeutics
September 25, 2024 04:11 ET
|
Research and Markets
Dublin, Sept. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Refractory Cough - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.The Chronic Refractory Cough (CRC)...
Alpha-1 Antitrypsin Drugs Global Strategic Research Report 2024: Advances in Biomarker Identification Generate New Opportunities for Targeted Therapies - Forecast to 2030
September 20, 2024 09:24 ET
|
Research and Markets
Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast to 2033: Focus on US, France, Germany, Italy, Spain, UK, and Japan
September 13, 2024 06:56 ET
|
Research and Markets
Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease (COPD): Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. In the...
Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Report and Company Analysis 2024-2032 Featuring AstraZeneca, Pfizer, GSK, Novartis, Astellas, Abbott, Boehringer Ingelheim, Almirall
September 10, 2024 05:12 ET
|
Research and Markets
Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease, Market Report, Forecast by Types, Treatment Types, Distribution Channels, Countries and Company Analysis,...
Respiratory Drugs - Market Insights, Competitive Landscape, and Industry Forecast to 2030; Featuring Company and Product Profiles of AstraZeneca, F. Hoffmann-La Roche, Teva Pharma, Novartis, GSK, and More
August 29, 2024 05:37 ET
|
Research and Markets
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The "Respiratory Drugs - Market Insights, Competitive Landscape, and Industry Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's...
Global Respiratory Drugs Market to Register Incremental Growth at a CAGR of ~6% by 2030 | DelveInsight
August 07, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Global Respiratory Drugs Market to Register Incremental Growth at a CAGR of ~6% by 2030 | DelveInsight The growing global prevalence of...
Acute Respiratory Distress Syndrome Analysis Report 2024: A $2.36 Billion Market by 2032 from $1.23 Billion in 2023
July 18, 2024 06:27 ET
|
Research and Markets
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Report by Type, End User, Regions and Company Analysis 2024-2032" report has been added to ...
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Report 2024: Comprehensive Insights About 65+ Companies and 70+ Pipeline Drugs
July 17, 2024 09:07 ET
|
Research and Markets
Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report...
United States Pulmonary/Respiratory Diseases KOLs Fair-Market Value Compensation Rates Report: An Independent Reference for Negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs)
July 10, 2024 05:29 ET
|
Research and Markets
Dublin, July 10, 2024 (GLOBE NEWSWIRE) -- The " Fair-Market Value Compensation Rates for Pulmonary/Respiratory Diseases KOLs - United States" report has been added to ResearchAndMarkets.com's...